GI Hepatobiliary

Hepatocellular Carcinoma

- Localized
  - No Prior Therapy
    - 1st Line
      - IRB #2377
        A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma
    - 2nd line
      - IRB #17603
        Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
      - IRB #19185
        Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

- Prior Therapy
  - IRB # 20506
    New study to be available soon

- No Trials Currently Available

- IRB #20410
  New study to be available soon

Cholangiocarcinoma

- 1st Line
  - IRB #19095
    A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

- 1" or 2" Line
  - IRB #16033
    New study to be available soon

CROSS-DISEASE TRIALS:

- IRB# TBD
  EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php